Related Experiment Video

Updated: May 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Serum lysophosphatidylcholine level is not altered in coronary artery disease

Sang Hoon Song1, Yeomin Yoon, Kyoung Un Park

  • 1Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Clinical Biochemistry
|April 17, 2012
PubMed

Insights

Serum lysophosphatidylcholine (LPC) levels do not differ in coronary artery disease (CAD) patients. This study found no association between LPC levels and CAD, suggesting it may not be a reliable biomarker for this condition.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Biomarker Discovery

Background:

  • Lysophosphatidylcholine (LPC) is recognized for its potential as a biomarker in atherosclerosis and phospholipase activity.
  • Investigating serum LPC levels in patients with coronary artery disease (CAD) is crucial for understanding its role in cardiovascular health.

Purpose of the Study:

  • To compare serum LPC levels between patients with CAD and healthy controls.
  • To explore the association of various LPC molecular species and their ratios with CAD.
  • To identify factors influencing serum LPC levels in the context of CAD.

Main Methods:

  • A cohort study involving 85 CAD patients and 105 controls.
  • Quantification of twelve LPC molecular species and lipid profiles in patient sera.
  • Statistical analysis to investigate associations with CAD and influencing factors.

Main Results:

  • No significant association was found between individual LPC species, inter-species ratios, or LPC to serum lipid ratios and CAD.
  • Diabetes was linked to reduced levels of LPC 16:1.
  • Sex significantly affected LPC ratios (e.g., LPC 16:0/LPC 18:1).
  • Current smokers exhibited a lower LPC 18:0/LPC 18:1 ratio.

Conclusions:

  • Serum LPC levels are not significantly altered in patients diagnosed with CAD via coronary angiography.
  • The study suggests that serum LPC may not serve as a direct biomarker for CAD.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...